Henk Mallo

机构：The Netherlands Cancer Institute · ORCID：0000-0001-6555-4942

发表论文 44 篇 · 总被引 2180 次 · h-index 18

代表论文

• Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma (2021 · Nature Medicine · 被引 342)
• Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up (2020 · Journal for ImmunoTherapy of Cancer · 被引 202)
• Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials (2023 · Annals of Oncology · 被引 136)
• Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM) (2020 · Melanoma Research · 被引 53)
• MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial (2022 · Immuno-Oncology Technology · 被引 44)
• Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study (2022 · Supportive Care in Cancer · 被引 24)